News

Fibrostatin presented its FST12 drug candidate for lung cancer in the 16th IASLC World Conference on Lung Cancer hosted by the IASLC International Association for the Study of the Lung Cancer that it was held from 6 to 9 September 2015 in Denver, Colorado (US).

FST12 is an inhibitor of the kinase activity of GPBP protein (Goodpasture antigen binding protein), whose overexpression is associated with cancer chemoresistance. FST12 emerges as an specific drug for chemoresistant and metastatic treatments of lung cancer.

Fibrostatin presented its FST12 drug candidate for lung cancer in the European Cancer Organization special conference on ‘Anticancer Drug Action and Drug Resistance: From Cancer Biology to the Clinic’, that it was held from 20 to 23 June 2015 in the Palazzo dei Congressi, Florence, Italy.

FST12 is an inhibitor of the kinase activity of GPBP protein (Goodpasture antigen binding protein), whose overexpression is associated with cancer chemoresistance. FST12 emerges as an specific drug for chemoresistant and metastatic treatments of lung cancer.